OpenAI is expanding its consumer reach, enterprise offerings, and infrastructure partnerships while navigating valuation, cash burn, and regulatory risks as it eyes a future public debut.

In life sciences, OpenAI advanced GPT-Rosalind, a model suite designed for drug discovery and experimental design under a trusted-access framework, aiming to collaborate with government research projects.

Security is tightening with Lockdown Mode for ChatGPT to reduce prompt injection and data exfiltration, strengthening enterprise positioning for confidential or regulated data environments.

OpenAI was named a Leader in Gartner’s Magic Quadrant for enterprise AI coding agents, underscoring its focus on mission-critical and regulated workflows.

Codex has grown to over 5 million weekly active users, with new plugins and features like Sites and Annotations to embed AI across data analytics, creative tasks, sales, investing, and other knowledge-intensive roles.

Plans to relaunch ChatGPT as a 'super app' that bundles coding tools and autonomous agents to drive higher-value paid offerings and unify revenue streams.

The plugin ecosystem has expanded to 62 connected apps and 110 specialized skills, with Frontier models and Codex now generally available on AWS to boost distribution and security compliance for enterprises.

OpenAI launched the OpenAI Deployment Company, backed by over $4 billion, to fund deep integration of its systems into corporate infrastructure.

Policy discussions touched on potential US government equity stakes in AI firms and the idea of a Public Wealth Fund, which could influence capital structure and governance ahead of any listing.

OpenAI is moving toward a full-stack enterprise AI platform and reportedly filed for a private IPO with a post-money valuation around $852 billion, while balancing slower growth with high AI infrastructure costs.